Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 19 December 2025 - 24 December 2025

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

Merck (MRK) Stock After Hours Today: Shares Hit a New 52-Week High on Dec. 24, 2025 — What to Know Before U.S. Markets Reopen

NEW YORK — December 24, 2025: Merck & Co., Inc. (NYSE: MRK) ended a holiday-shortened Christmas Eve session near $106.45, up about 1.3% on the day, and held close to those levels in thin after-hours trading. MarketBeat The move capped a strong late-December run for the pharmaceutical blue chip and came as the broader U.S. market pushed to fresh records in a “Santa rally” setup—an upbeat backdrop that helped lift several Dow components, including Merck. Reuters+1 Below is what investors and traders should know after the bell on 12/24/2025, and what to watch before the next U.S. cash-session open (note:
24 December 2025
··
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) stock surged in intraday trading on Wednesday, December 24, 2025, after the company released a fresh update on EDG-7500, its investigational therapy for hypertrophic cardiomyopathy (HCM). By late morning, shares were trading around $26.37—up roughly 21% versus the prior close—after swinging between about $21.30 and $27.05 on the day, with volume above 2.2 million shares. The move follows a company announcement that it has completed Parts B and C of its Phase 2 CIRRUS-HCM trial and reported favorable interim safety observations from Part D—an update that several market outlets characterized as a meaningful de-risking moment
24 December 2025
·
Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

Merck (MRK) Stock After Hours Today (Dec. 23, 2025): Shares Slip Slightly After the Close as Investors Track TrumpRx Pricing Deal, FDA Fast-Track Vouchers, and Fresh Wall Street Targets

NEW YORK — Merck & Co., Inc. (NYSE: MRK) ended regular trading Tuesday, December 23, 2025, at $105.04, and eased modestly in after-hours trading to about $104.81 (down roughly 0.2%) as of early evening in New York. Google The move after the bell was small, but MRK’s two-day run has been anything but: the stock is coming off a sharp gain on Monday (Dec. 22) and is trading within reach of its 52-week high—a setup that often makes the next session more about “what’s next” than what just happened. StockAnalysis+1 Below is what investors and traders will want on their
24 December 2025
··
Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb (BMY) Stock News Today: Supreme Court Bid, Drug-Pricing Deals, Dividend Boost, and 2026 Forecasts (Dec. 23, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) stock is back in the spotlight on Tuesday, December 23, 2025, as investors weigh a fast-moving U.S. drug-pricing landscape, fresh legal headlines tied to Medicare negotiations, and new analyst commentary on competitive pressure in a key growth product category. At the same time, Bristol Myers is heading into 2026 with a higher dividend, a defined near-term calendar (including a February earnings date), and intensifying debates over whether the stock’s “value” profile is a bargain—or a reflection of policy risk and the post-patent “reset” that still hangs over Big Pharma. BMY stock price today (December 23,
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock (NYSE: LLY) is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval. As of 15:11 UTC on Tuesday, LLY traded around $1,077, slightly above the prior close, after moving between roughly $1,057 and $1,088 during the session. The backdrop is simple but powerful: the obesity market is expanding fast, and the “next chapter” is about convenience, supply,
23 December 2025
···
Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is back in the market spotlight on December 23, 2025, with its stock hovering near the top of its 52-week range as a pair of momentum-friendly headlines land at once: a credit rating upgrade from S&P Global Ratings and a fresh bull-case valuation reset from Piper Sandler. Teva shares traded around $31.21, with the session pushing as high as roughly $31.28—also the top of its reported 52-week range ($12.47–$31.28). The company’s market cap was listed around $36.4 billion. Investing.com For investors, the big question now isn’t simply “why is TEVA stock moving today?” It’s
23 December 2025
·
GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins — What Analysts Forecast Next

GSK plc stock is ending 2025 with a dense cluster of catalysts—some bullish, some complicated, and all very “big pharma in an election-year policy blender.” Early Tuesday (Dec. 23, 2025), GSK’s ADR (NYSE: GSK) traded around $48.59, essentially flat on the session. Yahoo FinanceBehind that quiet tape, the company has been filing fresh buyback disclosures, reporting director share purchases, and navigating new US drug-pricing agreements—while continuing to stack up regulatory wins across respiratory and infectious disease. Below is what’s driving the GSK stock narrative right now, and how the latest forecasts and analyst views frame the next leg. What’s new
23 December 2025
·
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Ahead of the U.S. stock market open on Monday, December 22, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is stepping into a new spotlight—not just for biotech fundamentals, but also for a major index catalyst that can reshape short-term trading dynamics. As of the most recent close, ALNY last traded around $400.23, within a roughly $220–$500 52-week range. Below is what investors and traders typically want on their radar before the bell: the Nasdaq-100 inclusion effect, the latest regulatory and commercial momentum for Amvuttra, the most recent corporate/financial updates, and what Wall Street forecasts imply from here. What to know in
22 December 2025
···
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely to hinge less on quarterly fundamentals and more on the probability, timing, and conditions of closing. SEC+1 FOLD last traded around $14.18 (near the offer price), reflecting how quickly the market repriced the shares after the announcement. Investors.com Below is the week-ahead playbook: the latest news as of 21.12.2025, what Wall Street is saying, and the specific catalysts that could
22 December 2025
····
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen Inc. (NASDAQ: AMGN) heads into the Christmas-shortened trading week with a fresh wave of policy headlines, a newly expanded FDA label win in rare disease, and a market still laser-focused on what comes next for its obesity pipeline. Shares last traded around $327.38, following a session that ranged roughly between $323 and $331—levels that now matter even more in holiday-thinned liquidity. This coming week is also structurally different for U.S. equities: the NYSE closes early at 1:00 p.m. ET on Wednesday, Dec. 24, 2025 and is closed on Thursday, Dec. 25, 2025. That reduced time window can amplify single
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
···
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Dec. 21, 2025 — Pfizer Inc. (NYSE: PFE) ends the week in the spotlight after management laid out a 2026 outlook that undershot some Wall Street expectations, while a string of pipeline updates, partnerships, and policy headlines reshaped the near-term narrative around the long-time pharma bellwether. Reuters+1 Pfizer stock last closed at $25.25 on Friday, Dec. 19, with investors weighing whether the company’s cost-cutting and deal-making can offset the twin headwinds of fading COVID-era revenue and a looming patent cliff. Yahoo Finance+1 Why Pfizer stock is moving: the 2026 forecast reset The biggest driver of this week’s debate is Pfizer’s
21 December 2025
··
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF) business that has dominated its revenue for more than a decade? VRTX shares most recently closed at $456.20 on Friday, Dec. 19, up 1.97% in that session. StockAnalysis Below is the current news, forecasts, and market analysis shaping Vertex stock as of Dec. 20, 2025, including the latest on Casgevy’s pediatric data, Journavx’s commercial ramp, and a kidney-disease pipeline that
21 December 2025
··
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has kept Gilead stock near the top of its recent trading range—while also reopening the debate investors have wrestled with all year: how much upside can the pipeline deliver, and how much risk does U.S. pricing policy introduce? Below is a comprehensive look at what’s driving Gilead shares as of 20.12.2025, what analysts are forecasting next, and the key catalysts (and
20 December 2025
··
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) is ending mid-December 2025 in classic clinical-stage biotech fashion: big percentage swings, a sharp momentum breakout, and investors trying to decide whether the move is “new information” or simply “new positioning.” As of Saturday, December 20, 2025, EWTX is being widely quoted around $25.55—a level reached after a powerful jump in the prior U.S. session. StockAnalysis+1 What matters for readers tracking the stock isn’t just the price print. It’s the why: a late-stage neuromuscular story (sevasemten), a closely watched cardiovascular program (EDG-7500), and a pipeline that can re-rate quickly on clinical updates—up or down. PR
20 December 2025
·
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease). SEC+1 Below is a detailed breakdown of the latest news (as of 20.12.2025), plus the most relevant
20 December 2025
·····
AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Inc. (NYSE: ABBV) ended Friday’s session higher and then traded essentially flat in extended hours, as investors digested a major White House announcement on drug pricing—and noted that AbbVie is one of the last large pharma names still in talks with the administration. AbbVie stock price after the bell: where ABBV stands tonight AbbVie shares closed at $226.82, up 1.80% on Friday, Dec. 19, 2025. In after-hours trading, the stock was $226.81 (down about a penny) in the early evening—suggesting the market had largely “priced in” the day’s headlines by the close. StockAnalysis Friday’s session was active. ABBV traded
20 December 2025
·
Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target

Mirum Pharmaceuticals (MIRM) Stock Jumps on New $68.5M TCGX Financing, Bluejay Deal Momentum, and a Fresh $140 Price Target

December 19, 2025 — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is in the spotlight today after announcing additional financing tied to its planned Bluejay Therapeutics acquisition and drawing bullish analyst commentary that helped power a sharp move in the stock. As of the latest reported trade on Friday, December 19, 2025, MIRM was trading around $76.71, up about 9.15% from the prior close, after touching an intraday high near $77.19. What’s driving Mirum Pharmaceuticals stock today Two catalysts are dominating the narrative on 19.12.2025: That combination—fresh capital + pipeline-driven upgrade energy—is the kind of fuel that can move a mid-cap biotech
19 December 2025
·
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage pipeline. BioMarin Corporate+1 The acquisition is the latest example of a larger biotech company using M&A to secure near‑term revenue and strengthen long‑term growth, particularly in rare disease categories where commercialization requires specialized manufacturing, reimbursement know‑how, and tight engagement with
19 December 2025
····
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Inc. (NYSE: PFE) stock was essentially flat on Friday, Dec. 19, 2025, trading around $25.04 in midday trading, after a volatile week that blended policy headlines, a reset of near-term financial expectations, and fresh pipeline updates. For investors, the story around Pfizer stock right now is less about a single headline and more about a three-way tug-of-war: Below is a roundup of the most consequential Pfizer stock news, forecasts, and analysis points investors are digesting as of 19.12.2025. Pfizer stock price today: PFE steadies near $25 as investors weigh policy and guidance As of 14:16 UTC on Dec. 19,
19 December 2025
···
1 2 3 4 5 6 … 8

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop